AlloNK, a scalable allogeneic NK cell therapy, demonstrated high efficacy and safety in refractory RA, achieving a 71% ACR50 response rate and enabling community-based treatment. A phase III trial will launch soon, with broad market potential and additional autoimmune indications under evaluation.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.